Neumora Therapeutics is trading at $0.52, up 11.81% before the October 21, 2026 open, with broader biotech strength the clearest context. - The XBI rose 3.64% in the prior session, supporting a sector-led explanation. - Available reporting identified no fresh company-specific announcement. - Recent reports highlighted navacaprant trial setbacks, but these are not a new catalyst for this pre-market rise.